aggregation increased drastically for the peak concentration-treated group, while adenosine 5Ј-diCyclosporin A plays an important role in preventing phosphate-induced platelet aggregation did not rejection in allograft transplant recipients. Howreach statistical significance. Finally, in vitro plateever, the therapeutic use of cyclosporin A is associlet thromboxane A 2 generation increased in ated with increased incidence of thromboembolic cyclosporin A concentrations when platelets were complications and drug-related hypertension. In stimulated with either collagen or adenosine 5Ј-order to study the mechanisms by which cyclodiphosphate. In conclusion, both tested cyclosporin sporin A induces these abnormal pathophysiologi-A concentrations induced important changes in cal situations, we have assessed the platelet serotoplatelet serotonin and thromboxane content and nin contents and whole blood platelet aggregation aggregation, factors which may play a decisive role in control rats as well as in rats treated (orally) in the development and/or maintenance of hyperwith 30 and 5 mg/kg/day of cyclosporin A, after 2 tension and thrombotic complications. © 1999 and 7 weeks of treatment. These doses correspond Elsevier Science Ltd. All rights reserved. respectively to CsA "peak" and "trough" concentrations achieved in human blood in clinical prac-
tice (immediately following an intake of a daily bolic complications; Serotonin; Aggregation dose of CsA and when the blood concentration stabilizes, respectively). Both trough and peak C yclosporin A (CsA) is a potent and clinidoses caused an increase in blood pressure after 2 cally relevant immunosuppressive agent and 7 weeks. Platelet serotonin content decreased and is widely used in organ transplantain the cyclosporin-treated groups, in contrast with tion [1,2] and also in the treatment of autoimmune diseases [3] . However, despite its effectiveness, CsA therapy has been associated with drug-related Abbreviations: CsA, cyclosporin A; 5-HT, 5-hydroxytryptamine; TXA 2 , thromboxane A 2 ; PRP, platelet-rich plasma; ADP, adenohypertension [4] [5] [6] [7] and increased risk of thrombosine 5Ј-diphosphate; PPP, platelet-poor plasma; TXB 2 , thromboxembolic complications [8] [9] [10] , which may be partly ane B 2 ; SBP, systolic blood pressure; DBP, diastolic blood presdue to the direct effects of CsA on platelets [11] [12] [13] [14] .
sure; MBP, mean blood pressure. [17, 18] , in increased platelet aggregability [12- and Preparing the Platelets 14, 19] , as well as in altered peripheral serotonergic mechanisms [14, [20] [21] [22] . Serotonin (5-hydroxytrypFollowing intraperitoneal ketamine anesthesia, blood was withdrawn by venipuncture from the tamine, 5-HT), mainly present in platelets, has jugular vein and added to an anticoagulant solution been linked with thrombotic complication and in-(0.1 mL/mL blood) containing (in mmol/L) citric crease in blood pressure [23, 24] . When activated, acid (71), sodium citrate (85), and d-glucose (111). platelets adhere and aggregate to the damaged en-
The blood was centrifuged (160ϫg for 10 minutes dothelium, releasing (among other compounds) seat 20ЊC) to obtain platelet-rich plasma (PRP) and rotonin and thromboxane A2 (TXA 2 ), which may the platelets were then recovered by recentrifugaact as vasoconstrictors and also extend aggregation tion at 730ϫg for 10 minutes at 20ЊC. to other agonists, thus promoting thrombus formation.
1.3. Platelet Serotonin Contents Therefore, the purpose of this study was to determine the effects of CsA on the peripheral seroton-
The platelet pellet was resuspended in 1 mL of a ergic system, platelet aggregation, and TXA 2 genbuffer solution (pH 7. lamin (1 mmol/L), and 10% methanol. A flow rate (systolic, diastolic, and mean) were measured using of 1 mL/minute was maintained and detection of a tail-cuff sphygmomanometer. Thromboxane in the chromatographed serotonin was achieved by vitro studies were carried out through the incubausing a 141 Gilson electrochemical detector model tion of platelets with CsA (dissolved in dimethyl (650 mV). sulfoxide) at 0.1 and 1.0 mol/L concentrations. These concentrations were calculated to match the 1. 4 . Whole Blood Platelet Aggregation real blood concentrations of patients taking CsA: 1.0 mol/L immediately after an intake of a daily Whole blood platelet aggregation was monitored by measuring electric impedance, using a Chronodose of CsA ("peak") and 0.1 mol/L, when the log aggregometer (Chrono Log, Havertown, PA, the percentage of iodinated TXB 2 bound to a protein precipitate, and read from a standard curve. USA). This technique is based on the detection of All assays were performed in duplicate. changes in electrical resistance between two electrodes submerged in the sample. Fresh heparinized (0.5 mL) whole blood and 0.9% NaCl (0.5 mL)
1.6. Chemicals were mixed using a magnetic stirrer and allowed to balance at 37ЊC for 5 minutes before adding the Cyclosporin A (Sandimmun Neoral) was supplied by Novartis Farma, Lisbon, Portugal. ADP and agonists adenosine 5Ј-diphosphate (1.0 mol/L) collagen were obtained at Chrono-log Corp., Havand collagen (5 g/mL). Platelet count and mean ertown, PA, USA. A thromboxane B 2 radioimmuplatelet volume were measured with a Coulter noassay kit was purchased from R&D Systems, counter.
Abingdon, UK. All the other chemicals were of the highest analytical grade and were obtained from 1. 5 
. Platelet Thromboxane B 2 Generation
Sigma, St. Louis, MO, USA.
The blood was collected into plastic syringes con-1.7. Statistical Analysis taining 1 vol of 3.8% trisodium citrate for every 9 vol of blood. Aliquots were incubated for 3 hours Data are expressed as meansϮSEM of n experiat 37ЊC with either solvent (control) or CsA in ments. Groups were tested for differences by using final concentrations of 0.1 and 1.0 mol/L. The ANOVA and Student's t test. remaining blood was divided into aliquots containing CsA or solvent to measure the potentially maximum amount of releasable thromboxane.
Results
After incubation, whole blood samples were centrifuged as described previously to obtain PRP and 2.1. Blood Pressures platelet-poor plasma (PPP). Platelets were counted using the Coulter counter (350,000Ϯ50,000 plateSystolic blood pressure (SBP), diastolic blood preslets/L). They were subsequently activated with sure (DBP), and mean blood pressure (MBP) mea-1.0 mol/L of ADP and 5 g/mL of collagen. Folsurements were performed in all rats of the control lowing aggregation, the supernatants were assessed and CsA-treated groups, before (0 week) and 2 to determine the amount of thromboxane B 2 and 7 weeks after initiating the CsA administra-[(TXB 2 ) the stable end product of TXA 2 ] genertions. The DBP increased significantly after 2 and ated. Briefly, the contents of the cuvette was trans-7 weeks of treatment in the CsA-treated groups, ferred to a microcentrifuge tube containing 10 especially in the CsA(5) group (week 2: 96Ϯ1, mol/L etylene-dinitrilo-tetraacetic acid and 10 119Ϯ2, and 114Ϯ1 mm Hg; week 7: 103Ϯ1, 114Ϯ2, mol/L indomethacin and centrifuged at 12,000ϫg and 112Ϯ1 mm Hg) (pϽ0.05) for control, CsA(5), for 4 minutes. The resulting supernatant was frozen and CsA(30), respectively (Table 1) . Similar at Ϫ70ЊC to later analyse the TXB 2 . A sample of changes were recorded for the SBP. After 2 weeks, PRP merely spun without the addition of ADP or an increase in the SBP was registered in the CsAcollagen was also assessed to serve as a control for treated groups (190Ϯ2 mm Hg for CsA5 and 179Ϯ1 any spontaneous TXB 2 generation. To determine mm Hg for CsA30), contrasting with the control the total amount of releasable TXB 2 in both the (163Ϯ1 mm Hg; pϽ0.05). In week 7, the figures presence and absence of CsA, 20 mol/L calcium were approximately the same as those in week 2 chloride was added to the initial aliquots, and the (Table 1 ). The MBP also increased for the two citrated blood was allowed to clot at 37ЊC for 30 CsA groups after 2 and 7 weeks, compared with minutes. Following centrifugation, the serum was the control (Table 1) . separated and stored at Ϫ70ЊC until analyzed for the total amount of TXB 2 generated. The amount 2.2. Platelet Serotonin Contents of TXB 2 released in both PRP and serum preparations was assessed by radioimmunoassay (R&D The platelet serotonin measurements in the control and CsA-treated groups (5 and 30 mg/kg/day) were Systems, Abingdon, UK), measured by calculating performed in week 0 (before starting the adminis-2. 3 . Whole Blood Platelet Aggregation trations) and in weeks 2 and 7. In week 0, the We tested the effects of cyclosporin A on whole platelet 5-HT concentration of the control group blood platelet aggregation induced by collagen (5 was similar to that of the CsA-treated groups (Figg/mL) and ADP (1.0 mol/L), after 2 and 7 weeks ure 1). In week 2, there was a decrease in the of treatment. Before the start of CsA administraplatelet serotonin contents of the CsA-treated tions, similar values were obtained for platelet aggroups in contrasting to the control group [in ng/ gregation in the control and the CsA-treated mL: 1105Ϯ41 for control, 899Ϯ25 for CsA(5) and groups. Thus, only one mean is presented in week 698Ϯ21 for CsA(30); pϽ0.05]. Similar results were 0, which expresses values from the three groups obtained in week 7: 999Ϯ24 for control, 877Ϯ17 for (Table 2) . After 2 weeks of treatment, no statistiCsA(5), and 672Ϯ19 ng/mL for CsA (30) , pϽ0.05 cally significant increases in ADP-induced whole (Figure 1) . blood platelet aggregation were identified. In the CsA-treated groups, values for collagen-induced aggregation were significantly increased after the second week of treatment compared to those of the control group. These changes were most noticeable in the group that received 30 mg/kg/day of CsA. The results after 7 weeks of administration more or less confirmed those obtained after the second week (Table 2) .
Platelet Thromboxane B 2 Generation
Baseline supernatant TXB 2 levels were 251.8Ϯ7.9 ng/mL in control platelets compared to 315.6Ϯ8.3 ng/mL and 304.5Ϯ8.1 ng/mL (pϽ0.05) in CsA- lets were stimulated with collagen, there was a sig- nificant increase in TXB 2 release for both CsA three groups of rats at any stage of the study (Table 2) . concentrations compared to control (Figure 2 ). Serum TXB 2 levels that were generated in control and CsA-treated whole blood allowed to clot were 321Ϯ10.4 ng/mL for control and 342Ϯ12.3 and
Discussion
297Ϯ9.4 ng/mL (pϽ0.05) for 0.1 and 1.0 mol/L The present investigation was aimed at studying of CsA (not shown).
the peripheral serotonergic system, platelet aggregation, and blood pressure of rats treated with 2. 5 
. Platelet Count and Mean Platelet Volume
cyclosporin A at 5 and 30 mg/kg/day after 2 and 7 weeks of administration. These CsA concentraAs control parameters, we also counted the platetions were chosen because they corresponded to lets and measured the mean platelet volume. No different stages of the CsA absorption in clinical significant differences were obtained between the practice. Therefore, 30 mg/kg/day of CsA administered to a rat represents the peak value of CsA achieved in human blood immediately following an intake of a daily dose, whereas 5 mg/kg/day in the rat corresponds to the trough concentration after blood concentration stabilization. The choice of the 2-and 7-week time periods was based on the fact that 2 weeks could correspond to an acute situation and 7 weeks to a chronic situation. The blood pressures rose significantly in the rats of the CsA-treated groups (5 and 30 mg/kg/day) after both 2 and 7 weeks of administration. So, as we initially expected, both trough and peak concentrations were really effective in increasing blood pressures. Serotonin, due to its proaggregatory and also important physiological alterations, especially re-garding thrombotic and hypertensive effects. In maximal platelet activation after 2 hours but reverted to normal after 4 hours, thus suggesting that this study we have identified a decrease in platelet sustained exposure is needed to activate platelets 5-HT contents in both CsA-treated groups. Similar consistently. In fact, they did not observe the same results were already obtained by others in a CsA reversion in patients taking cyclosporin A: platelet treatment patient situation [14] and also in other activation at trough levels increased, but underhypertensive situations [25] [26] [27] . Low platelet serowent a further increase at peak concentrations. tonin concentration may be due to decreased upTheir results are in agreement with those obtained take or increased release, as was documented in by Vanrenterghem et al. [8] , who point out a posiother studies, both in CsA [14] and non-CsA intive link between CsA levels and enhanced aggreduced hypertension [25, 28] . If serotonin is abnorgation. Our results confirmed the nonsignificant mally released by platelets, an increase in the increases in ADP-induced aggregation and the sigplasma concentration of this amine could be exnificant increases in aggregatory response to collapected and consequently an increased deposition gen, already obtained by Malyszko et al. [14] and on collagen fibres of the vessel wall, thus promoting Taylor et al. [32] , and the positive link between direct vasoconstriction and platelet aggregation CsA levels (trough and peak) and increases in colamplification. In agreement with our hypothesis, lagen-induced aggregation, extending the results several papers have already reported that the inobtained by Grace et al. [12] and Vanrenterghem crease in whole blood and plasma 5-HT is intensiet al. [8] . fied during CsA treatment [14, 20, 22] and in other Confirming a platelet state of hyperactivity, we hypertensive situations as well [25, 27] . On the other have obtained significant increases in platelet hand, cyclosporin A induces endothelial damage TXA 2 release at baseline and by platelet stimula- [29, 30] that may contribute to increased vasocontion with both ADP and collagen. Peak-trough difstrictor response and platelet aggregation [31] .
ferences were observed by collagen stimulation in Thus, considering the above-mentioned inforagreement with aggregation results and also with mation, an increase in platelet aggregation with platelet 5-HT content results, thus suggesting a proCsA treatment is expected. In our study, whole portional relationship between CsA levels, thromblood platelet aggregation induced by collagen, but boxane, and 5-HT release and platelet aggregation. not by ADP, was increased in the rats of the CsAIn conclusion, this study points out that both treated groups when compared with control, as also CsA concentrations that we tested influence blood was shown in other studies carried out by other pressure, platelet serotonin, and thromboxane coninvestigators. In kidney transplant recipients, Matents and aggregation. Increased platelet aggregalyszko et al. [14] found that CsA increased collation, together with increased proaggregating and gen-and ADP-induced whole blood and PRP agvasoconstricting agents concentration (at least gregation when compared with healthy volunteers.
5-HT and TXA 2 ), near a damaged and/or dysfuncHowever, by ADP stimulation whole blood and tional vessel wall might provide the conditions to PRP aggregations were not statistically significant, intensify vasoconstriction and platelet thrombus formation, which may certainly contribute to the as was also confirmed by Taylor et al. control. Grace et al. [12] demonstrated that platelet aggregation was increased in response to subthreshold doses of several agonists, such as ADP and epinephrine, in in vitro studies with cyclosporin
